Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. develops precision therapeutics for serious diseases by targeting the chromatin regulatory system and correcting abnormal gene expression. The company’s news centers on oncology programs derived from its Gene Traffic Control® platform, including FHD-909, a selective SMARCA2 inhibitor for SMARCA4-mutant cancers, and selective CBP, EP300 and ARID1B degrader programs across ER+ breast cancer, multiple myeloma and other hematologic malignancies.
Recurring updates also cover the company’s collaboration with Lilly, preclinical data presentations, financial results, registered direct financing activity, executive appointments and investor-conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.